comp_molregno,act_standard_units,act_standard_type,act_activity_comment,act_bao_endpoint,act_type,ass_assay_id,ass_description,ass_assay_type,ass_assay_category,ass_chembl_id,doc_doi,doc_pubmed_id,doc_chembl_id,doc_title,doc_doc_type,doc_abstract,doc_patent_id,coms_canonical_smiles,comp_full_molformula,mold_chembl_id,act_0,act_1
JPYQGQXYBDPPCO-UHFFFAOYSA-N,nM,GI50,,BAO_0000189,GI50,,104370,Antagonist activity at androgen receptor in human LNCAP cells assessed as cell growth inhibition after 144 hrs by SRB assay,,,28272894,3093,10.1021/acs.jmedchem.7b00105,CHEMBL4007465,"1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.","Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G.","Prostate cancer (PC) is the fifth leading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for PC treatment, even though the disease frequently progresses toward androgen-independent forms. Most of the commercially available nonsteroidal antiandrogens show a common scaffold consisting of two aromatic rings connected by a linear or a cyclic spacer. By taking advantage of a facile, one-pot click chemistry reaction, we report herein the preparation of a small library of novel 1,4-substituted triazoles with AR antagonistic activity. Biological and theoretical evaluation demonstrated that the introduction of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of small molecules with improved overall AR-antagonist activity. In fact, compound 14d displayed promising in vitro antitumor activity toward three different prostate cancer cell lines and was able to induce 60% tumor growth inhibition of the CW22Rv1 in vivo xenograft model. These results represent a step toward the development of novel and improved AR antagonists.","InChI=1S/C17H10F4N4S/c18-12-2-5-15(6-3-12)26-10-13-9-25(24-23-13)14-4-1-11(8-22)16(7-14)17(19,20)21/h1-7,9H,10H2",0.49,-2.53,16750.0,
JXHMXVHKHQBPDZ-UHFFFAOYSA-N,nM,GI50,,BAO_0000189,GI50,,104370,Antagonist activity at androgen receptor in human LNCAP cells assessed as cell growth inhibition after 144 hrs by SRB assay,,,28272894,3093,10.1021/acs.jmedchem.7b00105,CHEMBL4007465,"1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.","Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G.","Prostate cancer (PC) is the fifth leading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for PC treatment, even though the disease frequently progresses toward androgen-independent forms. Most of the commercially available nonsteroidal antiandrogens show a common scaffold consisting of two aromatic rings connected by a linear or a cyclic spacer. By taking advantage of a facile, one-pot click chemistry reaction, we report herein the preparation of a small library of novel 1,4-substituted triazoles with AR antagonistic activity. Biological and theoretical evaluation demonstrated that the introduction of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of small molecules with improved overall AR-antagonist activity. In fact, compound 14d displayed promising in vitro antitumor activity toward three different prostate cancer cell lines and was able to induce 60% tumor growth inhibition of the CW22Rv1 in vivo xenograft model. These results represent a step toward the development of novel and improved AR antagonists.","InChI=1S/C20H13F3N6O2/c21-20(22,23)18-7-15(4-3-14(18)9-25)26-19(30)11-29-10-16(27-28-29)12-31-17-5-1-13(8-24)2-6-17/h1-7,10H,11-12H2,(H,26,30)",0.65,-2.38,6420.0,
LKJPYSCBVHEWIU-KRWDZBQOSA-N,nM,GI50,,BAO_0000189,GI50,,104370,Antagonist activity at androgen receptor in human LNCAP cells assessed as cell growth inhibition after 144 hrs by SRB assay,,,28272894,3093,10.1021/acs.jmedchem.7b00105,CHEMBL4007465,"1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.","Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G.","Prostate cancer (PC) is the fifth leading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for PC treatment, even though the disease frequently progresses toward androgen-independent forms. Most of the commercially available nonsteroidal antiandrogens show a common scaffold consisting of two aromatic rings connected by a linear or a cyclic spacer. By taking advantage of a facile, one-pot click chemistry reaction, we report herein the preparation of a small library of novel 1,4-substituted triazoles with AR antagonistic activity. Biological and theoretical evaluation demonstrated that the introduction of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of small molecules with improved overall AR-antagonist activity. In fact, compound 14d displayed promising in vitro antitumor activity toward three different prostate cancer cell lines and was able to induce 60% tumor growth inhibition of the CW22Rv1 in vivo xenograft model. These results represent a step toward the development of novel and improved AR antagonists.","InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)/t17-/m0/s1",0.56,-1.64,1800.0,
QFTHKNDEWVDULR-UHFFFAOYSA-N,nM,GI50,,"Entry 0: BAO_0000189, Entry 1: BAO_0000189, ",GI50,,"Entry 0: 104370, Entry 1: 104370, ","Entry 0: Antagonist activity at androgen receptor in human LNCAP cells assessed as cell growth inhibition after 144 hrs by SRB assay, Entry 1: Antagonist activity at androgen receptor in human LNCAP cells assessed as cell death after 144 hrs by SRB assay, ",,,"Entry 0: 28272894, Entry 1: 28272894, ","Entry 0: 3093, Entry 1: 3093, ","Entry 0: 10.1021/acs.jmedchem.7b00105, Entry 1: 10.1021/acs.jmedchem.7b00105, ","Entry 0: CHEMBL4007465, Entry 1: CHEMBL4007465, ","Entry 0: 1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment., Entry 1: 1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment., ","Entry 0: Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G., Entry 1: Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G., ","Entry 0: Prostate cancer (PC) is the fifth leading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for PC treatment, even though the disease frequently progresses toward androgen-independent forms. Most of the commercially available nonsteroidal antiandrogens show a common scaffold consisting of two aromatic rings connected by a linear or a cyclic spacer. By taking advantage of a facile, one-pot click chemistry reaction, we report herein the preparation of a small library of novel 1,4-substituted triazoles with AR antagonistic activity. Biological and theoretical evaluation demonstrated that the introduction of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of small molecules with improved overall AR-antagonist activity. In fact, compound 14d displayed promising in vitro antitumor activity toward three different prostate cancer cell lines and was able to induce 60% tumor growth inhibition of the CW22Rv1 in vivo xenograft model. These results represent a step toward the development of novel and improved AR antagonists., Entry 1: Prostate cancer (PC) is the fifth leading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for PC treatment, even though the disease frequently progresses toward androgen-independent forms. Most of the commercially available nonsteroidal antiandrogens show a common scaffold consisting of two aromatic rings connected by a linear or a cyclic spacer. By taking advantage of a facile, one-pot click chemistry reaction, we report herein the preparation of a small library of novel 1,4-substituted triazoles with AR antagonistic activity. Biological and theoretical evaluation demonstrated that the introduction of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of small molecules with improved overall AR-antagonist activity. In fact, compound 14d displayed promising in vitro antitumor activity toward three different prostate cancer cell lines and was able to induce 60% tumor growth inhibition of the CW22Rv1 in vivo xenograft model. These results represent a step toward the development of novel and improved AR antagonists., ","InChI=1S/C19H13ClF3N5O2/c20-17-6-3-13(7-16(17)19(21,22)23)25-18(29)10-28-9-14(26-27-28)11-30-15-4-1-12(8-24)2-5-15/h1-7,9H,10-11H2,(H,25,29)",0.63,-2.49,5090.0,15700.0
RLMHOMPROCVROL-UHFFFAOYSA-N,nM,GI50,,BAO_0000189,GI50,,104370,Antagonist activity at androgen receptor in human LNCAP cells assessed as cell growth inhibition after 144 hrs by SRB assay,,,28272894,3093,10.1021/acs.jmedchem.7b00105,CHEMBL4007465,"1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.","Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G.","Prostate cancer (PC) is the fifth leading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for PC treatment, even though the disease frequently progresses toward androgen-independent forms. Most of the commercially available nonsteroidal antiandrogens show a common scaffold consisting of two aromatic rings connected by a linear or a cyclic spacer. By taking advantage of a facile, one-pot click chemistry reaction, we report herein the preparation of a small library of novel 1,4-substituted triazoles with AR antagonistic activity. Biological and theoretical evaluation demonstrated that the introduction of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of small molecules with improved overall AR-antagonist activity. In fact, compound 14d displayed promising in vitro antitumor activity toward three different prostate cancer cell lines and was able to induce 60% tumor growth inhibition of the CW22Rv1 in vivo xenograft model. These results represent a step toward the development of novel and improved AR antagonists.","InChI=1S/C17H10F4N4O/c18-12-2-5-15(6-3-12)26-10-13-9-25(24-23-13)14-4-1-11(8-22)16(7-14)17(19,20)21/h1-7,9H,10H2",0.66,-2.34,19230.0,
WMQVHOLNVVYIOK-UHFFFAOYSA-N,nM,GI50,,"Entry 0: BAO_0000189, Entry 1: BAO_0000189, ",GI50,,"Entry 0: 105525, Entry 1: 105525, ","Entry 0: Inhibition of AR signaling pathway in testosterone-stimulated human LNCAP cells assessed as cell growth inhibition after 6 days by MTT assay, Entry 1: Inhibition of AR signaling pathway in testosterone-stimulated human LNCAP cells assessed as cell growth inhibition by flow cytometry, ",,,"Entry 0: 28011219, Entry 1: 28011219, ","Entry 0: 550, Entry 1: 550, ","Entry 0: 10.1016/j.bmcl.2016.12.022, Entry 1: 10.1016/j.bmcl.2016.12.022, ","Entry 0: CHEMBL4041540, Entry 1: CHEMBL4041540, ","Entry 0: In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell., Entry 1: In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell., ","Entry 0: Cruz EC, Carecho AR, Saidel ME, Montanari CA, Leitão A., Entry 1: Cruz EC, Carecho AR, Saidel ME, Montanari CA, Leitão A., ","Entry 0: Prostate cancer is one of the most prevalent types of cancer in male population. It is a hormone driven disease, especially in its initial phase. Hence, androgen deprivation therapy (ADT) is the major chemotherapeutic effort and novel AR inhibitors with improved pharmacological profiles are needed. In this report, a novel bioactive compound was selected and investigated using in silico and cell-based assays. Neq0502 compound was selective for the testosterone stimulated AR-dependent prostate cancer cell (LNCaP, GI50=22.4μM) when compared with unstimulated LNCaP or AR-insensitive (DU145 and PC-3) cell lines. Cell cycle arrest study provided the same profile for Neq0502 and the reference drug enzalutamide. Moreover, this compound is not cytotoxic for fibroblast Balb/C 3T3 clone A31 cells up to 250μM, with a good selectivity ratio (SI>11), which could be used in compound optimization effort to a novel therapeutic alternative., Entry 1: Prostate cancer is one of the most prevalent types of cancer in male population. It is a hormone driven disease, especially in its initial phase. Hence, androgen deprivation therapy (ADT) is the major chemotherapeutic effort and novel AR inhibitors with improved pharmacological profiles are needed. In this report, a novel bioactive compound was selected and investigated using in silico and cell-based assays. Neq0502 compound was selective for the testosterone stimulated AR-dependent prostate cancer cell (LNCaP, GI50=22.4μM) when compared with unstimulated LNCaP or AR-insensitive (DU145 and PC-3) cell lines. Cell cycle arrest study provided the same profile for Neq0502 and the reference drug enzalutamide. Moreover, this compound is not cytotoxic for fibroblast Balb/C 3T3 clone A31 cells up to 250μM, with a good selectivity ratio (SI>11), which could be used in compound optimization effort to a novel therapeutic alternative., ","InChI=1S/C20H15N5OS/c1-12-5-6-16-15(7-12)18-19(25-16)20(23-11-22-18)27-10-17(26)24-14-4-2-3-13(8-14)9-21/h2-8,11,25H,10H2,1H3,(H,24,26)",0.42,-2.16,22400.0,22600.0
WXCXUHSOUPDCQV-UHFFFAOYSA-N,nM,GI50,,"Entry 0: BAO_0000189, Entry 1: BAO_0000189, ",GI50,,"Entry 0: 105525, Entry 1: 105525, ","Entry 0: Inhibition of AR signaling pathway in testosterone-stimulated human LNCAP cells assessed as cell growth inhibition after 6 days by MTT assay, Entry 1: Inhibition of AR signaling pathway in testosterone-stimulated human LNCAP cells assessed as cell growth inhibition by flow cytometry, ",,,"Entry 0: 28011219, Entry 1: 28011219, ","Entry 0: 550, Entry 1: 550, ","Entry 0: 10.1016/j.bmcl.2016.12.022, Entry 1: 10.1016/j.bmcl.2016.12.022, ","Entry 0: CHEMBL4041540, Entry 1: CHEMBL4041540, ","Entry 0: In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell., Entry 1: In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell., ","Entry 0: Cruz EC, Carecho AR, Saidel ME, Montanari CA, Leitão A., Entry 1: Cruz EC, Carecho AR, Saidel ME, Montanari CA, Leitão A., ","Entry 0: Prostate cancer is one of the most prevalent types of cancer in male population. It is a hormone driven disease, especially in its initial phase. Hence, androgen deprivation therapy (ADT) is the major chemotherapeutic effort and novel AR inhibitors with improved pharmacological profiles are needed. In this report, a novel bioactive compound was selected and investigated using in silico and cell-based assays. Neq0502 compound was selective for the testosterone stimulated AR-dependent prostate cancer cell (LNCaP, GI50=22.4μM) when compared with unstimulated LNCaP or AR-insensitive (DU145 and PC-3) cell lines. Cell cycle arrest study provided the same profile for Neq0502 and the reference drug enzalutamide. Moreover, this compound is not cytotoxic for fibroblast Balb/C 3T3 clone A31 cells up to 250μM, with a good selectivity ratio (SI>11), which could be used in compound optimization effort to a novel therapeutic alternative., Entry 1: Prostate cancer is one of the most prevalent types of cancer in male population. It is a hormone driven disease, especially in its initial phase. Hence, androgen deprivation therapy (ADT) is the major chemotherapeutic effort and novel AR inhibitors with improved pharmacological profiles are needed. In this report, a novel bioactive compound was selected and investigated using in silico and cell-based assays. Neq0502 compound was selective for the testosterone stimulated AR-dependent prostate cancer cell (LNCaP, GI50=22.4μM) when compared with unstimulated LNCaP or AR-insensitive (DU145 and PC-3) cell lines. Cell cycle arrest study provided the same profile for Neq0502 and the reference drug enzalutamide. Moreover, this compound is not cytotoxic for fibroblast Balb/C 3T3 clone A31 cells up to 250μM, with a good selectivity ratio (SI>11), which could be used in compound optimization effort to a novel therapeutic alternative., ","InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",0.55,-1.50,120.0,290.0
